PEPLIN PHARMACEUTICALS FOR LIFE - Trademark Details
Status: 710 - Cancelled - Section 8
Serial Number
78484582
Registration Number
3235825
Word Mark
PEPLIN PHARMACEUTICALS FOR LIFE
Status
710 - Cancelled - Section 8
Status Date
2013-12-06
Filing Date
2004-09-16
Registration Number
3235825
Registration Date
2007-05-01
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s)
Typeset
Design Searches
260328 - Miscellaneous designs with overall oval shape, including amoeba-like shapes and irregular ovals.
Published for Opposition Date
2007-02-13
Attorney Name
Law Office Assigned Location Code
L50
Employee Name
JENKINS JR, CHARLES L
Statements
Amendment to a Registration/Renewal Certificate
In the statement, Column 2, lines 3 through 12 " democratic carcinoma, democratically cancer, antigenic myeloid metals, alpace, anglo-saxon, plastic anemia, abstractional, ataxia-eaglets, brain stem glom, brain and cans tumors, cans tumors" should be deleted, and adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, angio-sarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, brain stem glioma, brain and CNS tumors should be inserted.
Disclaimer with Predetermined Text
"pharmaceuticals"
Description of Mark
The mark consists of Word and propeller-type design.
Goods and Services
Vaccines, pharmaceuticals, medical preparations, diagnostic preparations and therapeutic agents for the treatment, prevention and diagnosis of diabetes, dermatological, respiratory and/or inflammatory conditions, namely, acne, angina, arthritis, aspiration pneumonia, emphysema, gastroenteritis, intestinal flu, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy; Vaccines, pharmaceuticals, medical preparations, diagnostic preparations and therapeutic agents for the treatment of cancers, namely, tumors, sarcomas, carcinomas and melanomas including tumors of the colon, breast, neck, throat, bladder, brain, liver, pancreas, adrenal glands, lymph, testicles, uterus, ovaries, lung as well solid and blood borne tumors such as ABL1 protooncogene, AIDS related cancers, acoustic neuroma, acute lymphocyte leukemia, acute myeloid leukemia,adenocystic carcinoma, adrenocrtical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angio-sarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma, bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, dermatofibrosarcoma-protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, fallopian tube cancer, fanconi anemia, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestational-trophoblastic-disease, glioma, gynecological cancers, hematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, intraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, Langerhan's-cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, Li-Fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, male breast cancer, malignant-rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer, ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral-neuroectodermal-tumors, pituitary cancer, polycythemia vera, prostate cancer, rare-cancers-and-associated-disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, salivary gland cancer, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer of the bladder, transitional-cell-cancer of the renal, pelvis and ureter, trophoblastic cancer, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom's-macroglobulinemia and Wilms' tumor
Goods and Services
Research and development, in relation to medical, biological and/or chemical diagnostic preparations, namely the identification evaluation and development of pharmaceuticals, pharmaceuticals for the treatment, prevention and diagnosis of diabetes, dermatological, respiratory and/or inflammatory conditions, namely, acne, angina, arthritis, aspiration pneumonia, emphysema, gastroenteritis, intestinal flu, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy; Research and development in relation to cancers including tumors, sarcomas, carcinomas and melanomas including tumors of the colon, breast, neck, throat, bladder, brain, liver, pancreas, adrenal glands, lymph, testicles, uterus, ovaries, lung as well solid and blood borne tumors such as ABL1 protooncogene, AIDS related cancers, acoustic neuroma, acute lymphocytic leukemia, acute myeloid leukemia, adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft-part sarcoma, anal cancer, angiosarcoma, aplastic anemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma, bladder cancer, bone cancers, bowel cancer, brain stem glioma, brain and CNS tumors, breast cancer, CNS tumors, carcinoid tumors, cervical cancer, childhood brain tumors, childhood cancer, childhood leukemia, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancers, cutaneous T-cell lymphoma, dermatofibrosarcoma-protuberans, desmoplastic-small-round-cell-tumor, ductal carcinoma, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extra-hepatic bile duct cancer, eye cancer, fallopian tube cancer, fanconi anemia, fibrosarcoma, gall bladder cancer, gastric cancer, gastrointestinal cancers, gastrointestinal-carcinoid-tumor, genitourinary cancers, germ cell tumors, gestational-trophoblastic-disease, glioma, gynecological cancers, hematological malignancies, hairy cell leukemia, head and neck cancer, hepatocellular cancer, hereditary breast cancer, histiocytosis, Hodgkin's disease, human papillomavirus, hydatidiform mole, hypercalcemia, hypopharynx cancer, intraocular melanoma, islet cell cancer, Kaposi's sarcoma, kidney cancer, Langerhan's-cell-histiocytosis, laryngeal cancer, leiomyosarcoma, leukemia, Li-Fraumeni syndrome, lip cancer, liposarcoma, liver cancer, lung cancer, lymphedema, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, male breast cancer, malignant-rhabdoid-tumor-of-kidney, medulloblastoma, melanoma, Merkel cell cancer, mesothelioma, metastatic cancer, mouth cancer, multiple endocrine neoplasia, mycosis fungoides, myelodysplastic syndromes, myeloma, myeloproliferative disorders, nasal cancer, nasopharyngeal cancer, nephroblastoma, neuroblastoma, neurofibromatosis, Nijmegen breakage syndrome, non-melanoma skin cancer, non-small-cell-lung-cancer, ocular cancers, oesophageal cancer, oral cavity cancer, oropharynx cancer, osteosarcoma, ostomy ovarian cancer, pancreas cancer, paranasal cancer, parathyroid cancer, parotid gland cancer, penile cancer, peripheral-neuroectodermal-tumors, pituitary cancer, polycythemia vera, prostate cancer, rare-cancers-and-associated-disorders, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, Rothmund-Thomson syndrome, salivary gland cancer, schwannoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumors, squamous cell carcinoma, stomach cancer, synovial sarcoma, testicular cancer, thymus cancer, thyroid cancer, transitional-cell-cancer of the bladder, transitional-cell-cancer of the renal, pelvis, ureter, trophoblastic cancer, urethral cancer, urinary system cancer, uroplakins, uterine sarcoma, uterus cancer, vaginal cancer, vulva cancer, Waldenstrom's-macroglobulinemia and Wilms' tumor
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
2 - Sec. 8 - Entire Registration
Class Status Date
2013-12-06
Primary Code
005
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
2 - Sec. 8 - Entire Registration
Class Status Date
2013-12-06
Primary Code
042
Correspondences
Name
Simor L. Moskowitz
Address
Please log in with your Justia account to see this address.
Foreign Application Information
Filing Date | Application Number | Country | Foreign Priority Claim In |
2004-03-18 | 994165 | Australia | True |
0000-00-00 | Australia | False |
Trademark Events
Event Date | Event Description |
2004-09-22 | NEW APPLICATION ENTERED IN TRAM |
2005-04-17 | ASSIGNED TO EXAMINER |
2005-04-27 | NON-FINAL ACTION WRITTEN |
2005-04-27 | NON-FINAL ACTION MAILED |
2005-10-26 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2005-10-26 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2005-11-01 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2005-11-23 | SUSPENSION LETTER WRITTEN |
2005-11-23 | LETTER OF SUSPENSION MAILED |
2006-01-27 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2006-01-27 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2006-02-10 | AMENDMENT FROM APPLICANT ENTERED |
2006-03-31 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2006-04-05 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
2006-03-31 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2006-04-06 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2006-05-05 | NON-FINAL ACTION WRITTEN |
2006-05-05 | NON-FINAL ACTION MAILED |
2006-11-02 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2006-11-02 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2006-11-08 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2006-11-29 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2006-12-14 | ASSIGNED TO LIE |
2006-12-15 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
2007-01-24 | NOTICE OF PUBLICATION |
2007-02-13 | PUBLISHED FOR OPPOSITION |
2007-05-01 | REGISTERED-PRINCIPAL REGISTER |
2007-06-07 | PAPER RECEIVED |
2007-06-07 | SEC 7 REQUEST FILED |
2007-07-12 | ASSIGNED TO PARALEGAL |
2007-08-01 | AMENDMENT UNDER SECTION 7 - ISSUED |
2013-09-05 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
2013-12-06 | CANCELLED SEC. 8 (6-YR) |